Chronic treatment with infliximab, an anti-TNF-α antibody, prevented endothelial dysfunction of the brachial artery in patients with rheumatoid arthritis (RA) [38], systemic vasculitis [39] and Crohn’s disease [40]. The gene discussed is TNF; the disease is necrotizing vasculitis.